STARPHARMA HOLDINGS LTD SPONSORED ADR A (OTCMKTS:SPHRY) showed a decrease of 40% in shares shorted. FINRA announced shares shorted of SPHRY’s total 1,800 shares. That’s 40% down from 3,000 shares. STARPHARMA HOLDINGS LTD SPONSORED ADR A (OTCMKTS:SPHRY) has 3,600 shares average volume. It’ll cost 1 days for SPHRY to restore its previous position.

SPHRY touched $7.13 during the last trading session after $0.09 change.Starpharma Holdings Limited has 5,100 shares volume, 194.29% up from normal. SPHRY is and has moved 0.00% since March 11, 2018. SPHRY underperformed the S&P500 by 4.37%.

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.The firm is worth $266.44 million. The firm focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom.Currently it has negative earnings. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer.

A couple more Starpharma Holdings Limited (OTCMKTS:SPHRY) news were released by: Seekingalpha.com which released on April 13, 2018 “Starpharma (SPHRY) Presents At OTCQX International Virtual Investor Conference – Slideshow – Seeking Alpha”, also Prnewswire.com on January 24, 2018 released “OTC Markets Group Announces the 2018 OTCQX Best 50 – PR Newswire”, the next Prnewswire.com is “Starpharma Commences Bacterial Vaginosis Prevention Study of VivaGel(R) – PR Newswire” on August 15, 2011. Seekingalpha.com has article titled “Starpharma: At Last It Is Happening – Seeking Alpha”.